Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects

Florenzo Iannone, Francesco Trotta, Carlomaurizio Monteccuco, Roberto Giacomelli, Mauro Galeazzi, Marco Matucci-Cerinic, Clodoveo Ferri, Maurizio Cutolo, Lisa Maria Bambara, Giovanni Triolo, Gianfranco Ferraccioli, Gabriele Valentini, Giovanni Lapadula

Research output: Contribution to journalArticle

Abstract

Objective: To evaluate the efficacy of switching to etanercept treatment in patients with rheumatoid arthritis who already responded to infliximab, but presented side effects. Methods: Charts of 553 patients with rheumatoid arthritis were retrospectively reviewed to select patients who responded to the treatment with infliximab and switched to etanercept because of occurrence of adverse effects. Clinical data were gathered during 24 weeks of etanercept treatment and for the same period of infliximab treatment before infliximab was stopped. Disease Activity Score computed on 44 joints (DAS-44), erythrocyte sedimentation rate (ESR) 1st hour, Visual Analogue Scale (VAS) of pain, Health Assessment Questionnaire (HAQ), and C reactive protein (CRP) were assessed every 8 weeks. Results: 37 patients were analysed. Adverse events to infliximab were mostly infusion reactions. No statistically significant difference between infliximab, before withdrawal, and etanercept, after 24 weeks, was detected in terms of DAS-44 (2.7 and 1.9, respectively), HAQ (0.75 and 0.75, respectively), ESR (21 and 14, respectively) and CRP (0.5 and 0.3, respectively). VAS pain decreased significantly after switching to etanercept treatment (40 and 24, respectively; p

Original languageEnglish
Pages (from-to)249-252
Number of pages4
JournalAnnals of the Rheumatic Diseases
Volume66
Issue number2
DOIs
Publication statusPublished - Feb 2007

Fingerprint

Rheumatoid Arthritis
amsonic acid
Blood Sedimentation
Pain Measurement
Sedimentation
C-Reactive Protein
Health
Therapeutics
Visual Analog Scale
Etanercept
Infliximab
Joints
Surveys and Questionnaires

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. / Iannone, Florenzo; Trotta, Francesco; Monteccuco, Carlomaurizio; Giacomelli, Roberto; Galeazzi, Mauro; Matucci-Cerinic, Marco; Ferri, Clodoveo; Cutolo, Maurizio; Bambara, Lisa Maria; Triolo, Giovanni; Ferraccioli, Gianfranco; Valentini, Gabriele; Lapadula, Giovanni.

In: Annals of the Rheumatic Diseases, Vol. 66, No. 2, 02.2007, p. 249-252.

Research output: Contribution to journalArticle

Iannone, F, Trotta, F, Monteccuco, C, Giacomelli, R, Galeazzi, M, Matucci-Cerinic, M, Ferri, C, Cutolo, M, Bambara, LM, Triolo, G, Ferraccioli, G, Valentini, G & Lapadula, G 2007, 'Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects', Annals of the Rheumatic Diseases, vol. 66, no. 2, pp. 249-252. https://doi.org/10.1136/ard.2006.058776
Iannone, Florenzo ; Trotta, Francesco ; Monteccuco, Carlomaurizio ; Giacomelli, Roberto ; Galeazzi, Mauro ; Matucci-Cerinic, Marco ; Ferri, Clodoveo ; Cutolo, Maurizio ; Bambara, Lisa Maria ; Triolo, Giovanni ; Ferraccioli, Gianfranco ; Valentini, Gabriele ; Lapadula, Giovanni. / Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. In: Annals of the Rheumatic Diseases. 2007 ; Vol. 66, No. 2. pp. 249-252.
@article{f893dfe8cc7541c99d03fcff16adf1dc,
title = "Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects",
abstract = "Objective: To evaluate the efficacy of switching to etanercept treatment in patients with rheumatoid arthritis who already responded to infliximab, but presented side effects. Methods: Charts of 553 patients with rheumatoid arthritis were retrospectively reviewed to select patients who responded to the treatment with infliximab and switched to etanercept because of occurrence of adverse effects. Clinical data were gathered during 24 weeks of etanercept treatment and for the same period of infliximab treatment before infliximab was stopped. Disease Activity Score computed on 44 joints (DAS-44), erythrocyte sedimentation rate (ESR) 1st hour, Visual Analogue Scale (VAS) of pain, Health Assessment Questionnaire (HAQ), and C reactive protein (CRP) were assessed every 8 weeks. Results: 37 patients were analysed. Adverse events to infliximab were mostly infusion reactions. No statistically significant difference between infliximab, before withdrawal, and etanercept, after 24 weeks, was detected in terms of DAS-44 (2.7 and 1.9, respectively), HAQ (0.75 and 0.75, respectively), ESR (21 and 14, respectively) and CRP (0.5 and 0.3, respectively). VAS pain decreased significantly after switching to etanercept treatment (40 and 24, respectively; p",
author = "Florenzo Iannone and Francesco Trotta and Carlomaurizio Monteccuco and Roberto Giacomelli and Mauro Galeazzi and Marco Matucci-Cerinic and Clodoveo Ferri and Maurizio Cutolo and Bambara, {Lisa Maria} and Giovanni Triolo and Gianfranco Ferraccioli and Gabriele Valentini and Giovanni Lapadula",
year = "2007",
month = "2",
doi = "10.1136/ard.2006.058776",
language = "English",
volume = "66",
pages = "249--252",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "2",

}

TY - JOUR

T1 - Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects

AU - Iannone, Florenzo

AU - Trotta, Francesco

AU - Monteccuco, Carlomaurizio

AU - Giacomelli, Roberto

AU - Galeazzi, Mauro

AU - Matucci-Cerinic, Marco

AU - Ferri, Clodoveo

AU - Cutolo, Maurizio

AU - Bambara, Lisa Maria

AU - Triolo, Giovanni

AU - Ferraccioli, Gianfranco

AU - Valentini, Gabriele

AU - Lapadula, Giovanni

PY - 2007/2

Y1 - 2007/2

N2 - Objective: To evaluate the efficacy of switching to etanercept treatment in patients with rheumatoid arthritis who already responded to infliximab, but presented side effects. Methods: Charts of 553 patients with rheumatoid arthritis were retrospectively reviewed to select patients who responded to the treatment with infliximab and switched to etanercept because of occurrence of adverse effects. Clinical data were gathered during 24 weeks of etanercept treatment and for the same period of infliximab treatment before infliximab was stopped. Disease Activity Score computed on 44 joints (DAS-44), erythrocyte sedimentation rate (ESR) 1st hour, Visual Analogue Scale (VAS) of pain, Health Assessment Questionnaire (HAQ), and C reactive protein (CRP) were assessed every 8 weeks. Results: 37 patients were analysed. Adverse events to infliximab were mostly infusion reactions. No statistically significant difference between infliximab, before withdrawal, and etanercept, after 24 weeks, was detected in terms of DAS-44 (2.7 and 1.9, respectively), HAQ (0.75 and 0.75, respectively), ESR (21 and 14, respectively) and CRP (0.5 and 0.3, respectively). VAS pain decreased significantly after switching to etanercept treatment (40 and 24, respectively; p

AB - Objective: To evaluate the efficacy of switching to etanercept treatment in patients with rheumatoid arthritis who already responded to infliximab, but presented side effects. Methods: Charts of 553 patients with rheumatoid arthritis were retrospectively reviewed to select patients who responded to the treatment with infliximab and switched to etanercept because of occurrence of adverse effects. Clinical data were gathered during 24 weeks of etanercept treatment and for the same period of infliximab treatment before infliximab was stopped. Disease Activity Score computed on 44 joints (DAS-44), erythrocyte sedimentation rate (ESR) 1st hour, Visual Analogue Scale (VAS) of pain, Health Assessment Questionnaire (HAQ), and C reactive protein (CRP) were assessed every 8 weeks. Results: 37 patients were analysed. Adverse events to infliximab were mostly infusion reactions. No statistically significant difference between infliximab, before withdrawal, and etanercept, after 24 weeks, was detected in terms of DAS-44 (2.7 and 1.9, respectively), HAQ (0.75 and 0.75, respectively), ESR (21 and 14, respectively) and CRP (0.5 and 0.3, respectively). VAS pain decreased significantly after switching to etanercept treatment (40 and 24, respectively; p

UR - http://www.scopus.com/inward/record.url?scp=33846875483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846875483&partnerID=8YFLogxK

U2 - 10.1136/ard.2006.058776

DO - 10.1136/ard.2006.058776

M3 - Article

C2 - 16837489

AN - SCOPUS:33846875483

VL - 66

SP - 249

EP - 252

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 2

ER -